7Baggers
 Lipocine Advances Phase 3 Trial for PPD Treatment  MSN Fri, 03 Oct 2025 02:17:01 GMT
 Lipocine reports one-third enrollment in PPD treatment trial By Investing.com  Investing.com Nigeria Wed, 01 Oct 2025 06:40:57 GMT
 Progress Update: LPCN 1154 for the Treatment of Postpartum Depression  Psychiatric Times Tue, 30 Sep 2025 15:31:34 GMT
 lipocine advances phase 3 trial for ppd treatment  TipRanks Tue, 30 Sep 2025 13:57:14 GMT
 lipocine reports one-third enrollment in ppd treatment trial  Investing.com India Tue, 30 Sep 2025 12:41:29 GMT
 Lipocine, Inc. Stock Plummets to New 52-Week Low of $2.65  Markets Mojo Sat, 27 Sep 2025 01:39:25 GMT
 Lipocine Seeks Regulatory Clarity on LPCN 2401 Study  TipRanks Fri, 26 Sep 2025 14:00:30 GMT
 Lipocine, Inc. Hits New 52-Week Low at $2.68 Amid Declining Sales  Markets Mojo Thu, 25 Sep 2025 20:13:48 GMT
 published on: 2025-09-12 01:07:34  Newser Fri, 12 Sep 2025 06:07:34 GMT
 Lipocine to Present at Global Investment Conference  TipRanks Fri, 05 Sep 2025 07:00:00 GMT
 Lipocine Participates in H.C. Wainwright Investor Conference  TipRanks Fri, 05 Sep 2025 07:00:00 GMT
 published on: 2025-09-04 06:09:03  Newser Thu, 04 Sep 2025 11:09:03 GMT

Lipocine Inc
(NASDAQ:LPCN) 

LPCN stock logo

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of...

Full Time Employees: 12
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends